NeurosciencePLoS PathogensPeer-reviewed
PrP turnover in vivo and the time to effect of prion disease therapeutics
Taylor L Corridon, Jill O’Moore, Alyssa Seerley…·Eric Vallabh Minikel
The paper measures PrP half-life in vivo and shows it limits the time to effect of PrP-lowering therapies, with implications for drug development and clinical trial design.